Symrise AG

First-half sales were EUR 2.539 billion, with organic growth of 2%. Q2 sales were EUR 1.22 billion, and organic sales increased 4.5% with 5.1% volume growth and 0.7% negative pricing. Gross profit was EUR 1.05 billion and gross margin was 41.3%, essentially in line with last year. Adjusted EBITDA was EUR 553 million with a 21.8% margin; management said this was down 30 basis points versus the prior year. Adjusted business free cash flow increased 47% year over year to EUR 347 million, or 13.7% of sales, up 450 basis points. For 2026, Symrise reaffirmed organic growth of 2% to 4%, adjusted EBITDA margin of 21.5% to 22.5%, and adjusted business free cash flow margin above 14%. Management said Q3 organic sales growth should be similar to Q2 and that the full-year outlook is supported by stronger momentum, resilient core end markets, and moderating FX headwinds.

Jean-Yves Parisot emphasized that momentum improved as the quarter progressed, with Q2 organic growth of 4.5% driven by stronger volumes, commercial execution, and broad strength in North America and Asia Pacific. He framed the first half as validation of the ONE Symrise strategy and said the company is moving from planning to implementation in its ONE SYM transformation. His tone was constructive and confident, but he repeatedly stressed that the company is still balancing growth, profitability, and investment in a challenging environment.

Olaf Klinger highlighted resilient first-half profitability and strong cash generation despite higher freight/logistics costs tied to the Middle East, timing lags on surcharges, and continued investment. He said gross profit was EUR 1.05 billion with a 41.3% margin, adjusted EBITDA was EUR 553 million with a 21.8% margin, and adjustments were EUR 9.3 million for M&A, legal, and ONE SYM costs. He called out adjusted business free cash flow of EUR 347 million, or 13.7% of sales, and said H1 performance supports the full-year objective of above 14%; he also noted net debt rose from EUR 2.1 billion to EUR 2.3 billion, equity ratio improved to 49.2%, and net leverage was 2.2x adjusted EBITDA, within target range. On capital allocation, he said the buyback program was around EUR 192 million invested at half year and is targeting EUR 400 million by end-October.

Analysts focused on whether the strong cash flow was structural or timing-driven; Olaf said the improvement mainly reflected disciplined working capital, better supplier payment terms, inventory discipline, and CapEx control, and that there was no exceptional tax effect or other one-off behind H1. Questions also centered on Pet Nutrition pricing and the growth mix in Scent & Care and regional performance. Management said Pet Nutrition is still affected by tactical price reductions, but these are now smaller than last year and should normalize next year, while Scent & Care pricing declines were described as tactical volume-vs-price tradeoffs, with profitability supported by operational excellence and commercial actions. On Q3, management guided to growth broadly similar to Q2 and said the pipeline looks healthy across Food & Beverage, fragrance, care, and pet.